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Introduction
Malignant mesothelioma (MM) is an aggressive tumor of the pleura, peritoneum and, occasionally, pericardium and tunica vaginalis testis. Epidemiological and experimental studies have linked the development of MM with the exposure to asbestos or erionite fibers (1, 2) .
Genetics and co-factors influence the risk of developing MM following exposure to asbestos and erionite (3) (4) (5) . About 3,000 cases of MM are diagnosed each year in the US, and median survival is 1 year from diagnosis. Five-year survival is unusual and limited to patients diagnosed in the early stages of the disease (6) . More than 90% of MM are diagnosed at late stages, when the tumor is resistant to conventional therapy. Chemotherapy remains as the mainstay of MM treatment, although the standard chemotherapy for MM, pemetrexed/cisplatin, only extends survival by an average of 11 weeks (7). Given the recent major progress in the development of monoclonal antibody (mAb)-based immunotherapy for the treatment of some solid tumors, immunotherapy for MM is of interest (8) . Targets for antibody-based treatment regimens for MM need to be defined. CSPG4 consists of an N-linked glycoprotein of 280 kDa and a proteoglycan component of about 450 kDa (9) and plays an important role in melanoma cell proliferation, migration and metastasis (10) . NG2, the rat homologue of CSPG4, binds directly to collagen types II, V and VI (CII, CV and CVI) and is critical for adhesion of glioma cells (11) . CSPG4-specific mAbs have been shown to disrupt melanoma cell adhesion to collagen type I (CI), CVI and fibronectin (FN) (12, 13) . Through its binding to ECM components such as CI, CIV, CVI and FN, CSPG4 modulates cell polarization, adhesion, spreading and survival via activation of FAK, Src and ERK1/ERK2 (14, 15) . Notably, MM cells are capable of adhering to CI, CIV and FN (16) .
CSPG4 is over-expressed on melanoma cells and on triple negative breast cancer cells; in 
Cell lines:
The MM cell lines Con, Gard, Gor, PPM-Mill, Phi and Rob were established from surgically resected human MM specimens and characterized for their mesothelial origin (21) .
Hmeso cell line was also established and characterized from human MM (22) . The MM cell line Ren was provided by Dr. Steven Albelda (University of Pennsylvania, Philadelphia, PA) (23) .
The Burkitt's lymphoma Raji and the melanoma Colo38 cell lines were used as negative and positive controls, respectively. All cell lines were cultured in Dulbecco's modified Eagle's medium, DMEM (Gibco, Grand Island, NY), 10% FBS at 37°C in a 5% CO 2 atmosphere.
Primary human mesothelial cells (HM) isolated from pleural effusions of seven patients with congestive heart failure were obtained from Queen's Medical Center, Honolulu, HI and cultured in DMEM supplemented with 20% FBS as described (24) .
Western blotting: Cell lysates were prepared by using M-PER SDS-based lysing buffer (Invitrogen, Carlsbad, CA) and immunoblotting was performed as previously described (25), followed by enhanced chemiluminescence (SuperSignal West Pico Chemiluminescent Substrate,
Rockford, IL).
Flow cytometry analysis: Subconfluent MM cells were incubated with 1 ȝg mAbs for 1 hour at 4°C. Cell surface CSPG4 expression was measured as previously described (26) .
Immunohistochemistry (IHC):
IHC was performed on FFPE sections. Antigen retrieval and tissue section processing were performed by standard procedures.
siRNA transfection: Cells were transfected with CSPG4 Stealth RNAi siRNA from Invitrogen (Carlsbad, CA) using Lipofectamine 2000 Reagent (Invitrogen, Carlsbad, CA). Stealth RNAi siRNA with high GC content was used as a negative control ("scramble").
Cell viability assay:
Cell viability of MM cells was measured after treatments with 10 ȝg/mL Cell adhesion assay: Cells preincubated with mAb TP41.2 or IgG control, were plated onto dishes pre-coated with FN, CI, CIV, LN (10ȝg/ml) and cultured at 37 °C for 1 hour. Adherent cells were fixed with 2% glutaraldehyde and stained with 0.5% crystal violet. Dye was resolved in 10% acetic acid and 560nm absorbance was measured by a multi-well spectrophotometer (UV-VIS).
Migration and Invasion assays:
MM cell motility and invasiveness were assayed in Transwell® plates as previously described (27) after pre-incubation with mAb TP41.2 or IgG control.
Wound healing assay:
A distinct area was wounded by a micropipette tip on cultures of MM cells transiently transfected with CSPG4 siRNA, or pre-incubated with mAb TP41.2,. Cell motility into wounded areas was evaluated by microscopy following a 24 and 48 hour incubation at 37ºC. The number of cells migrated into the wound area was quantified by Image J software.
Apoptosis assay: MM cells were pre-incubated with mAb TP41.2 or IgG control and apoptosis was evaluated by Annexin V/7-AAD staining as previously described (27) .
Anchorage-independence assay: MM cells were incubated with mAb TP41.2 or IgG control and the growth in soft agar was assayed as previously described (28) . Briefly, MM cells (5X10 ͵ ) incubated with mAb TP41.2 or IgG control (10ug/ml) were seeded on 0.3% agarose overlaid onto solidified 0.6% agarose in DMEM 10% FBS. Plates were fed every 48 h with mAbs. The growth in soft agar was assayed 17 days later. Colonies larger than 0.15 mm in diameter were scored using Biorad colony counter. Colonies were counted in 5 selected fields from representative of 3 wells per treatment. The experiments were repeated 3 times. ͺ gene (PPM-Mill/luc) were injected into the peritoneal cavity of SCID mice as previously described (22) . After luciferin injection, xenografts were visualized by luminescence using the In Vivo Imaging System (IVIS™, Xenogen Corp., Alameda, CA). In the experiments designed to inhibit MM tumor growth, five mice per group were injected with PPM-Mill/luc cells preincubated with mAb TP41.2 or IgG control (the treatment started at D0). Mice were treated with mAbs twice a week (0.2 mg mAb/mouse/injection) for four weeks. In experiments designed to evaluate the therapeutic efficacy of treatment with mAb TP41.2, PPM-Mill/luc were injected into mice. At day 5 (D5) after tumor challenge (when tumors were imageable), animals were divided in two groups to equate average tumor growth. Animals were injected with mAb TP41.2 or IgG control (200 μg/ml/mouse), twice a week for four weeks. Tumor growth was evaluated by IVIS every seven days.
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Statistical Analysis: Data were collected from three independent experiments. Differences between treated groups were analyzed by Student t-test (unpaired), one-way or two-way Analysis of Variance (ANOVA). Differences were considered to be significant if P < 0.05.
Survival was compared by the log-rank test. All statistical analyses were performed using the GraphPad Prism 5 software.
Results
CSPG4 is expressed in Malignant Mesothelioma cells
We examined the expression of CSPG4 on MM cells and on HM with mAbs 225.28, Table 1 ).
In summary, these data show that CSPG4 is expressed in 6/8 MM cell lines tested, 24/48 tumor biopsies, and was not detectable in HM from 5 different patients of congestive heart failure. The selective expression of CSPG4 in MM prompted us to investigate whether CSPG4 is a suitable target for therapeutic intervention in MM.
CSPG4-specific mAbs inhibit MM cell growth by blocking cell adhesion
To understand the possible role of CSPG4 in MM we analyzed the effect of CSPG4 gene Previous reports have shown that CSPG4 binds to ECM components and that CSPG4-specific mAbs can disrupt these interactions (29) . To verify the efficacy of CSPG4-specific mAbs in MM, PPM-Mill, Hmeso and REN cells were pre-treated with either mAb TP41.2 or with IgG control before plating on dishes pre-coated with CI, CIV and FN. Cell counting following a 30 minutes incubation revealed that the number of adherent PPM-Mill and Hmeso cells pre-incubated with mAb TP41.2 was significantly (p<0.05) lower than that of cells treated with IgG control. In contrast, mAb TP41.2 had no effect on adhesion of CSPG4-negative REN cells ( Fig. 2A) . The CSPG4 specificity of the effect of mAb TP41.2 is supported by CSPG4 expression on PPM-Mill cells and by its lack of expression on REN cells also when they are cultured in ECM-coating culture conditions ( Supplementary Fig. S3A ).
We next analyzed whether the inhibition of the CSPG4-mediated interaction with ECM components by mAb TP41.2 affects MM cell viability. mAb TP41. 
CSPG4-specific mAb TP41.2 reduces migration and invasion of MM cells.
Research. (Fig. 3B) .
These results indicate that CSPG4 plays an important role in cell motility and invasion of MM cells and that mAb TP41.2 affects the invasive properties of MM cells.
As the Transwell ® assay measures directional migration towards a chemoattractant gradient, we also performed a wound-healing assay to compare non-directional motility.
Research. Fig. S5 ). These findings were corroborated by the inhibition of wound closure of PPM-Mill cells, but not of REN cells, by CSPG4 siRNA-mediated silencing (Supplementary Fig.   S6 ).
CSPG4-specific mAb TP41.2 reduces anchorage independent growth of MM cells.
To determine whether treatment of MM cells with mAb TP41.2 suppresses anchorage independent growth, we analyzed the formation of colonies in soft agar. PPM-Mill and REN cells were treated with mAb TP41.2 or with IgG control before plating in soft agar and cultured for further 17 days supplementing antibodies daily. The number and size of colonies were markedly reduced when PPM-Mill cells were pre-incubated with mAb TP41.2 compared to IgG control treated cells (Fig. 4A) . On the contrary, no significant differences in the number or size of colonies were observed in REN cells treated with IgG control or mAb TP41.2 (Fig. 4B) .
These results indicate that mAb TP41.2 antagonizes anchorage-independent growth of MM cells and support the role of CSPG4 in the maintenance of the malignant phenotype in MM.
CSPG4-specific mAb TP41.2 induces apoptosis of MM cells.
We analyzed whether mAb TP41. 
CSPG4-specific mAb TP41.2 inhibits the growth of MM cells in SCID mice
We assessed the in vivo anti-tumor activity of mAb TP41.2 against MM xenografts by using two approaches: 1) Inhibition of MM growth and 2) Therapy of MM, as described in Material and Methods. In the experiment aimed at inhibiting tumor growth, the treatment with TP41.2 monoclonal antibody was initiated in parallel with intraperitoneum cell injection. In the experiment on the possible therapeutic effect of CSPG4 targeting, tumors were allowed to grow, before initiating the treatment with mAb TP41.2. In this model, 5 days after injection the tumors were 3 mm in diameter. We established that this size was clearly measurable by IVIS and in previous papers we showed that tumors of this size were responsive to anti-tumor treatments (27, 32) . In the tumor inhibition experiment a delay in growth was observed in the group treated with mAb TP41.2 compared to the control treated group (Fig. 6A) . Tumor growth was significantly (P<0.0001) inhibited by mAb TP41.2 within 4 weeks, as compared to IgG control treated mice.
The rate of tumor growth in the treated group was lower than that in the IgG control treated group even after the end of treatment, and the growth delay was maintained until the termination of the study (Fig. 6B) . Analysis of survival showed a significant (P=0.001) increase in median survival of mAb TP41.2 treated mice, as compared to IgG control treated animals (Fig. 6C ).
In the MM therapy experiment mAb TP41.2-mediated control of tumor growth was ͳͷ observed by day 14 after tumor challenge (Fig. 6D) . Treatment with mAb TP41.2 significantly reduced average tumor volume as compared to IgG control for the entire duration of treatment (P<0.0001) (Fig. 6E) . Thereafter, tumors resumed growth by maintaining a slower pace.
Analysis of survival showed a significant (P=0.03) increase in median survival of mAb TP41.2 treated mice, compared to IgG control treated animals (Fig. 6F) . Thus, mAb TP41.2 caused a significant increase in survival.
In both survival experiments mice were euthanized and necropsied when tumor development caused severe ascites limiting the animal's mobility, according to IACUC regulations.
No signs of toxicity were detected in mice treated with mAb TP41.2. The experiments were terminated 9 months after tumor challenge. Animals treated with the IgG control died within 120 days in both experiments. In the inhibition of tumor growth experiment (Fig. 6A-C) 4 of the 5 mice treated with mAb TP41.2 survived for 140 days and one was still alive day 270. In the MM therapy experiment (Fig. 6D-F Together, these data indicate that mAb TP41.2 is a well tolerated and promising antitumor agent that is capable of inhibiting MM and prolonging survival. 
Discussion
CSPG4 is an attractive target for mAb-based immunotherapy for melanoma and breast cancer (18) and a number of CSPG4-specific mAbs, characterized for their specificity (20) , are now available. We show here that most MM cell lines and 60% of MM biopsies express high levels of CSPG4, while HM and normal pleura contain very low levels of CSPG4. The highest CSPG4 expression was found in 5 out 5 tested sarcomatoid tumors, a histological subtype that is completely resistant to present therapies (6), suggesting that CSPG4 could be a potential target also for therapy of those patients that currently have no available therapeutic options.
Our data indicate that CSPG4 influences MM cell viability and survival through the interaction with ECM. Cell adherence was higher on FN suggesting the occurrence of a positive feedback loop of FN that induces the expression of CSPG4, which has high binding affinity for FN. Moreover, CSPG4 is known to interact with Į4ȕ1 integrin, characterized as the FN cell receptor. This mechanism can enhance MM cell adhesion to FN in a CSPG4-dependent manner.
In support to this hypothesis, in melanoma cells a fragment of FN has been shown to bind CSPG4 directly to promote melanoma cell adhesion in a CSPG4-dependent manner (29) and to promote melanoma cell spreading on FN (33).
The link between CSPG4 and melanoma progression has been well documented by studying integrin-mediated adhesion and spreading, and the subsequent signaling involving CDC42, ACK1 and p130CAS, which in turn activate FAK, Src and ERK1/ERK2 (14, 15) . In MM cells adhered to FN we found that FAK phosphorylation induced by integrin engagement was decreased in CSPG4-expressing cells treated with mAb TP41.2. This result matches the observation that CSPG4 enhances FAK activation in melanoma cells (14) . Moreover, in breast cancer cells CSPG4 inhibition reduced Akt activity (26) . In accordance with these results, The previous characterization of the CSPG4 specific monoclonal antibody 225.28 (26) showed that the effects of a CSPG4 antibody on MM might be comparable to those of trastuzumab, widely used in breast cancer (37) . Both mAbs target cell surface receptors (CSPG4 and HER2, respectively) and consequently the downstream PI3K/Akt pathway (26) , which is critical for cell migration and survival. Moreover, trastuzumab targets the tumor vasculature of the tumor microenvironment controlling neo-angiogenesis (38) . Similarly, CSPG4-specific mAbs have been shown to reduce vascular density in melanoma (36) and breast cancer (26) Research. 
